The combined NSCLC market of Argentina, Brazil, and Mexico will grow at a rate of 6% per year between 2013 and 2018, and the number of NSCLC incident cases will increase by 25% between 2013 and 2023. Growing NSCLC population, changes in medical practice and reimbursement and the resulting continued uptake of targeted therapies, and entry of eleven new high-value branded agents are the key factors driving this market. In this report, we examine the trends within the NSCLC pharmaceutical markets of Argentina, Brazil, and Mexico, which are characterized by government-sponsored healthcare systems that have a wide population reach but impose limitations in terms of cancer drug coverage; growing uptake of biomarker-specific agents, in particular, EGFR inhibitors; and growing drug-treatable populations.
Primary research: 70 oncologists surveyed across Argentina. Separate in-depth interviews with 8 Argentine oncologists, 6 Brazilian oncologists, and 6 Mexican oncologists.
Epidemiology: Total incident cases of NSCLC in Argentina, Brazil, and Mexico over a ten-year period (2013-2023) by age, stage, histology, and gender.
Current therapies and medical practice: Reporting use of brands and generics for the NSCLC treatments available in Argentina, Brazil, and Mexico.
Pricing and reimbursement: Prices of NSCLC therapies in Argentina, Brazil, and Mexico versus other major markets and analysis of the impact of government reimbursement on treatment trends.
Market forecast features: Our analysis evaluates rates of NSCLC progression and rates of drug treatment with NSCLC therapies, across all stages of the disease. We include a forecast of current and emerging therapies within platinum agents, antitubulins, antimetabolites, other cytotoxic agents, angiogenesis inhibitors, EGFR inhibitors, ALK inhibitors, immunotherapies, and c-Met inhibitors from 2013 through 2018, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.